These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP. Kim YJ; Ichise M; Ballinger JR; Vines D; Erami SS; Tatschida T; Lang AE Mov Disord; 2002 Mar; 17(2):303-12. PubMed ID: 11921116 [TBL] [Abstract][Full Text] [Related]
28. Palliative care and its emerging role in Multiple System Atrophy and Progressive Supranuclear Palsy. Wiblin L; Lee M; Burn D Parkinsonism Relat Disord; 2017 Jan; 34():7-14. PubMed ID: 28341224 [TBL] [Abstract][Full Text] [Related]
29. Pain processing in atypical Parkinsonisms and Parkinson disease: A comparative neurophysiological study. Avenali M; Tassorelli C; De Icco R; Perrotta A; Serrao M; Fresia M; Pacchetti C; Sandrini G Clin Neurophysiol; 2017 Oct; 128(10):1978-1984. PubMed ID: 28829981 [TBL] [Abstract][Full Text] [Related]
30. Levodopa-induced oromandibular dystonia in progressive supranuclear palsy. Tan EK; Chan LL; Wong MC Clin Neurol Neurosurg; 2003 Apr; 105(2):132-4. PubMed ID: 12691807 [TBL] [Abstract][Full Text] [Related]
31. Subcortical dementia revisited: similarities and differences in cognitive function between progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and multiple system atrophy (MSA). Bak TH; Crawford LM; Hearn VC; Mathuranath PS; Hodges JR Neurocase; 2005 Aug; 11(4):268-73. PubMed ID: 16093227 [TBL] [Abstract][Full Text] [Related]
32. [Regional cerebral blood flow single photon emission tomography (SPECT) and magnetic resonance imaging (MRI) may be useful in the diagnosis of patients with cortico-basal degeneration, progressive supranuclear palsy and multiple system atrophy]. Lass P; Sławek J; Derejko M; Dubaniewicz M Neurol Neurochir Pol; 2003; 37 Suppl 5():263-74. PubMed ID: 15098354 [TBL] [Abstract][Full Text] [Related]
33. Comparison of clinical features in pathologically confirmed PSP and MSA patients followed at a tertiary center. Xie T; Kang UJ; Kuo SH; Poulopoulos M; Greene P; Fahn S NPJ Parkinsons Dis; 2015; 1():15007. PubMed ID: 28725681 [TBL] [Abstract][Full Text] [Related]
34. Clinical correlates of serum insulin-like growth factor-1 in patients with Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. Numao A; Suzuki K; Miyamoto M; Miyamoto T; Hirata K Parkinsonism Relat Disord; 2014 Feb; 20(2):212-6. PubMed ID: 24280021 [TBL] [Abstract][Full Text] [Related]
35. MRI evaluation of progressive supranuclear palsy: differentiation from Parkinson's disease and multiple system atrophy. Eraslan C; Acarer A; Guneyli S; Akyuz E; Aydin E; Colakoglu Z; Kitis O; Calli MC Neurol Res; 2019 Feb; 41(2):110-117. PubMed ID: 30373485 [TBL] [Abstract][Full Text] [Related]
36. Clinical features and natural history of progressive supranuclear palsy: a clinical cohort study. Nath U; Ben-Shlomo Y; Thomson RG; Lees AJ; Burn DJ Neurology; 2003 Mar; 60(6):910-6. PubMed ID: 12654952 [TBL] [Abstract][Full Text] [Related]
38. Clinical correlates of fear of falling in progressive supranuclear palsy and multiple system atrophy. Martínez-Villota VA; Terroba-Chambi C; Castillo-Torres SA; Rossi M; Merello M Eur J Neurol; 2023 Aug; 30(8):2261-2266. PubMed ID: 37183570 [TBL] [Abstract][Full Text] [Related]
39. Orofacial apraxia in corticobasal degeneration, progressive supranuclear palsy, multiple system atrophy and Parkinson's disease. Ozsancak C; Auzou P; Dujardin K; Quinn N; Destée A J Neurol; 2004 Nov; 251(11):1317-23. PubMed ID: 15592726 [TBL] [Abstract][Full Text] [Related]
40. Computerized posturography analysis of progressive supranuclear palsy: a case-control comparison with Parkinson's disease and healthy controls. Ondo W; Warrior D; Overby A; Calmes J; Hendersen N; Olson S; Jankovic J Arch Neurol; 2000 Oct; 57(10):1464-9. PubMed ID: 11030799 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]